Most material SEC filings — July 7, 2026

Envirotech Vehicles closed its merger with Azio AI on July 2, 2026, issuing 2,655,157 shares of common stock and 973,450 shares of convertible preferred stock (convertible 100:1) to acquire 100% of Azio AI. The combined company has deployed 6 MW of off-grid power in South Texas and secured rights to a 548-acre site capable of supporting 500 MW capacity. Leadership changed: Chris Young appointed CEO/Chairman, Simon Yu appointed President, Jason Maddox became CFO, and Phillip Oldridge departed as former CEO.

COMPASS Pathways reported positive Phase 3 data (COMP006, COMP005) for COMP360 psilocybin in treatment-resistant depression across >1,000 participants. COMP006 (N=581) met primary endpoint (p<0.001) with 25mg dose showing rapid onset (day 2) and durability through 26 weeks; 39% achieved clinically meaningful response at week 6. Safety profile favorable: 94.6% experienced adverse events but majority were transient and on treatment day only; serious adverse events low (5.7% in 25mg arm). Rolling NDA submission and FDA National Priority Voucher already granted; final submission expected Q4 2026; commercial launch targeted H1 2027 with ~578 treatment centers prepared. Market: 4M U.S. TRD patients and 13M PTSD patients identified.

Vivani Medical, Inc. (Seller) agreed to merge with ClearOne Inc. (Parent) via a forward merger of Parent's subsidiary into Cortigent, Inc. (Company). Seller, the sole owner of Company, will receive 12,500,000 shares of Parent Common Stock as consideration. Parent will simultaneously raise $10–15M (2.5–5M units at undisclosed pricing) via Financing, with each unit containing one common share and one warrant exercisable at $10/share for 6 months. The merger is structured as a tax-free reorganization under Section 368(a) of the Code. Seller's shares are subject to staggered lock-ups (50% for 1 year, 50% for 2 years). ThinkEquity LLC is financial advisor to Seller and Company.

Aptera Motors received its EPA Certificate of Conformity (CoC) on June 18, 2026, for the 2026 Launch Edition vehicle, confirming federal emissions compliance. This is one of two primary federal certifications required before U.S. vehicle sales; the company still must complete Federal Motor Vehicle Safety Standards (FMVSS) testing using its low-volume validation assembly line before customer deliveries can begin.

Microbot Medical reported greater than 100% revenue and customer growth in Q2 2026 (ended June 30) versus Q1 2026, following the April 13, 2026 Full Market Release of its LIBERTY Endovascular Robotic System. The company expanded sales territories from 4 to 8 in Q2 and plans to reach 12 by year-end 2026; entered into an agreement with Lovell Government Services to serve federal healthcare systems (VHA, MHS, IHS); received Israeli Ministry of Health marketing clearance; and established a second manufacturing site to support scaling.

Capstone Energy+ (formerly Capstone Green Energy Holdings) transitioned from OTC Markets (OTCQX: CGEH) to The Nasdaq Global Select Market under ticker symbol CEPL, effective July 8, 2026. The company cited strengthened financial foundation, simplified capital structure, and return to profitability over the past two years as justifications. No concrete financial metrics, deal amounts, or operational changes are detailed in the filing—it is a pure listing announcement.

BIO-key International (Nasdaq: BKYI, market cap ~$4.9M) announced on July 7, 2026 that Nasdaq approved reinstatement of its common stock trading effective July 8, 2026, following a June 16 hearing panel determination that the company regained compliance with continued listing standards including minimum bid price and SEC filing requirements. The company remains subject to a Discretionary Panel Monitor for one year (until July 6, 2027). No financial metrics, share count changes, or specific remediation actions are detailed in the filing.

On June 30, 2026, Glimpse Group sold its wholly-owned subsidiary Glimpse Learning LLC to Glimpse Learning Inc (a newly formed Wyoming company). Buyer issued Glimpse Group 1,999,999 shares (19.99% equity stake). Consideration also includes: (1) NIH payment of $58,000 if/when NIH invoice of $167,963 is collected by Sept 30, 2026; (2) $18,000 payments on Dec 1, 2026 and Mar 1, 2027; (3) royalties of 7% of revenue July 1, 2027–Dec 31, 2027, then 10% thereafter, capped at $1.2M total, with buyout option at $1M on Dec 30, 2027; (4) Buyer assumed liabilities and paid $200,000 working capital adjustment. Sale eliminates ~$890K of the company's ~$3.4M nine-month revenue (26% of top line) and ~$1.2M of ~$1.9M operating losses.

bioAffinity Technologies reported Q2 2026 CyPath Lung sales growth >200% year-over-year and 30% sequentially, with 155% increase in physician offices ordering the test versus Q2 2025. The company has now performed nearly 3,000 tests total since commercial launch, with expanding adoption across pulmonology practices, lung nodule clinics, academic centers, and VA facilities. No specific revenue dollar amounts, test pricing, or customer count are disclosed.

Tvardi announced Phase 1 results for TTI-109, a phosphate prodrug of its STAT3 inhibitor TTI-101. The study (three-part design, n=32 in MAD cohort) confirmed rapid conversion to TTI-101 within 2 hours at 95% efficiency, dose-proportional pharmacokinetics with exposures above STAT3 IC₅₀, and exploratory pharmacodynamic data showing up to 60% reductions in disease-relevant immune cell populations (Th17, Tfh, B cells). Critically, diarrhea duration with TTI-109 was substantially shorter (0.46 days) versus TTI-101 (3.35 days) at near-equivalent doses. Company plans Phase 2 trials in dermatologic and GI diseases, contingent on IND clearance and additional funding. Cash position: $25.0M; runway extends to Q4 2026.

Standard Nuclear, Inc. filed an amended S-1 registration statement for an IPO of 18,250,000 Class A shares priced at $18–$21 per share (midpoint $19.50), targeting $328–$383M gross proceeds. The company manufactures TRISO advanced nuclear fuel at Oak Ridge, Tennessee; expects operational facilities in Idaho and a joint venture with Framatome in Washington by late 2026; and reports $245M total contract backlog ($65M funded, $157M in purchase options, $23M contingent), plus $986M qualified pipeline. As of March 31, 2026, the company held $124.9M cash, a $79.9M accumulated deficit, and negative operating cash flow of $4.3M. Founder Thomas Hendrix will own ~59.5% voting power post-IPO (20-vote Class B shares).

As of July 3, 2026, Digi Power X held ~$155M in cash with zero long-term debt, having deployed ~$95M year-to-date into its Alabama data center campus entirely from internal resources. The company's flagship AI data center Phase 1 remains on track for December 2026 service, Phase 2 for Q1 2027, with all major long-lead equipment secured. NeoCloudz GPU-as-a-Service platform is live and generating AI revenues; FY2027 targets $250–300M annualized run rate across three segments: colocation ($80–200M), GPU-as-a-Service (~$100M), and energy sales (~$12M).

Turn Therapeutics completed a comprehensive interim analysis of its adaptive Phase 2 trial of GX-03 in atopic dermatitis (AD). The trial enrolled ~50 patients in Stage 1. Interim data showed clinically meaningful efficacy across a broader disease-severity spectrum than originally anticipated, including patients with mild-to-moderate AD (baseline EASI 1.1–7.0). The optimized Stage 2 design will now prospectively enroll ~120–135 patients stratified across the full EASI spectrum (1.1–7.0, 7.1–15.9, ≥16), evaluate four prespecified endpoints using FDA-recognized Hochberg multiple-testing procedure, and complete enrollment by Q4 2026. No serious adverse events or discontinuations have been reported; safety profile remains favorable. The company states it remains sufficiently capitalized through Q3 2027.

Spanish regulatory authority AEMPS authorized Theriva to begin VIRAGE2, a Phase 2a proof-of-concept trial with 6 patients evaluating more frequent dosing (≥3 doses, 2 months apart) of VCN-01 combined with standard-of-care chemotherapy in metastatic pancreatic cancer. The trial builds on positive VIRAGE Phase 2b results (112 patients) showing 2 doses of VCN-01 improved overall survival, progression-free survival, and duration of response versus single-dose or chemotherapy alone. Results will inform dosing for a potential future Phase 3 trial.

Axos Financial announced a definitive agreement to acquire Arc Technologies, Inc., a financial technology platform founded in 2021 serving technology and growth companies. Arc provides integrated cash management, capital markets, and AI-powered financial software solutions. The transaction is expected to close in July 2026, subject to customary closing conditions. No purchase price, stock consideration, or specific financial terms are disclosed in this filing.